Moderna–Caris Life Sciences: genomic profiling, 202310– strategic collab multi-year clinico-genomics data for mRNA-based precision cancer drugs

	Period	2023-10-24
	Partner, 1st	Moderna Inc. (Nasdaq: MRNA)
	Group	Moderna (Group)
	Partner, 2nd	Caris Life Sciences Inc.
	Group	Caris Life Sciences (Group)
	Product	genomic services
	Product 2	mRNA-based drug
	Person	Spetzler, David (Caris Life Sciences 202310 President)
	Person 2	Aanur, Praveen (Moderna 202310 VP Oncology Therapeutic Area Head)

Caris Life Sciences Inc.. (10/24/23). "Press Release: Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics". Irving, TX.

Partnership enables Moderna to leverage Caris’ vast library of de-identified, multi-modal data and analytics capabilities to accelerate precision medicine and the delivery of novel medicines to patients

Caris Life Sciences® (Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, today announced a new agreement with Moderna (NASDAQ:MRNA) in support of Moderna’s oncology and novel therapeutics initiatives.

Through this multi-year agreement, Moderna will leverage Caris’ vast library of de-identified, multi-modal data solutions derived from whole exome sequencing, whole transcriptome sequencing and protein analyses along with claims data to enhance development strategies for Moderna’s oncology pipeline, including facilitation of optimal clinical trial design, discovery of novel biomarkers and characterization of resistance mechanisms.

“Partnering with Caris Life Sciences will support Moderna’s oncology portfolio with clinico-genomics data from Caris’ industry-leading and comprehensive suite of integrated precision medicine capabilities,” stated Praveen Aanur, MD, MPH, MBA, Vice President, Oncology Therapeutic Area Head of Moderna.

“We are thrilled to partner with Moderna to impact and advance the field of cancer treatment with mRNA medicines, with a common goal of improving patient lives,” said David Spetzler, MS, PhD, MBA, President of Caris Life Sciences. “The aggregate strength of our combined molecular, data science and therapeutics technologies will support the predictive modeling of patient responses to therapies, and more generally, may help improve the probability of technical and regulatory success of Moderna’s innovative medicines.”

As the pioneer in precision medicine and molecular profiling, Caris has created the largest clinico-genomic database coupled with cognitive computing to unravel the molecular complexity of disease. Caris was the first in the industry to provide Whole Exome Sequencing DNA coverage and Whole Transcriptome Sequencing RNA coverage (WES / WTS) for every patient.

About Caris Life Sciences

Caris Life Sciences® is the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.

Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com.

Caris Life Sciences Media Contact:

Lisa Burgner
214.294.5606

Caris Life Sciences Business Development Contact:

Brian Lamon, Ph.D.
Chief Business Officer, Head of BioPharma Business Development
609.955.8883

Moderna Media Contact:

Chris Ridley
Vice President, Communications
617.800.3651
Chris.Ridley@modernatx.com